NCBI PubMed NLM PubMed
Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search for
  Limits  Preview/Index  History  Clipboard  Details     
About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central
Limits: 90 Day
 Show: 
Items 1 - 20 of 33
 
 of 2
Next  
1: Carlson SL. Related Articles, Links
No abstract Prostate disease.
RN. 2004 Sep;67(9):54-9; quiz 60. Review. No abstract available.
PMID: 15497350 [PubMed - indexed for MEDLINE]
2: Lepor H. Related Articles, Links
No abstract Radical prostatectomy: status and opportunities for improving outcomes.
Cancer Invest. 2004;22(3):435-44. Review. No abstract available.
PMID: 15493364 [PubMed - indexed for MEDLINE]
3: Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Related Articles, Links
Abstract Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
N Engl J Med. 2004 Oct 7;351(15):1513-20.
PMID: 15470214 [PubMed - indexed for MEDLINE]
4: Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Related Articles, Links
Abstract Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
N Engl J Med. 2004 Oct 7;351(15):1502-12.
PMID: 15470213 [PubMed - indexed for MEDLINE]
5: Debes JD, Tindall DJ. Related Articles, Links
No abstract Mechanisms of androgen-refractory prostate cancer.
N Engl J Med. 2004 Oct 7;351(15):1488-90. No abstract available.
PMID: 15470210 [PubMed - indexed for MEDLINE]
6: McDermott RS, Anderson PR, Greenberg RE, Milestone BN, Hudes GR. Related Articles, Links
Abstract Cranial nerve deficits in patients with metastatic prostate carcinoma: clinical features and treatment outcomes.
Cancer. 2004 Oct 1;101(7):1639-43.
PMID: 15468187 [PubMed - indexed for MEDLINE]
7: Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. Related Articles, Links
Abstract Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
Cancer. 2004 Oct 1;101(7):1569-74.
PMID: 15468186 [PubMed - indexed for MEDLINE]
8: Hoffman RM, Gilliland FD, Penson DF, Stone SN, Hunt WC, Potosky AL. Related Articles, Links
Abstract Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls.
Cancer. 2004 Nov 1;101(9):2011-9.
PMID: 15452835 [PubMed - indexed for MEDLINE]
9: Calabrese DA. Related Articles, Links
Abstract Prostate cancer in older men.
Urol Nurs. 2004 Aug;24(4):258-64, 268; quiz 269. Review.
PMID: 15446376 [PubMed - indexed for MEDLINE]
10: Qayyum A, Coakley FV, Lu Y, Olpin JD, Wu L, Yeh BM, Carroll PR, Kurhanewicz J. Related Articles, Links
Abstract Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging.
AJR Am J Roentgenol. 2004 Oct;183(4):1079-83.
PMID: 15385308 [PubMed - indexed for MEDLINE]
11: Everson KM, McQueen CE. Related Articles, Links
No abstract Lycopene for prevention and treatment of prostate cancer.
Am J Health Syst Pharm. 2004 Aug 1;61(15):1562-6. Review. No abstract available.
PMID: 15372829 [PubMed - indexed for MEDLINE]
12: Klein EA. Related Articles, Links
No abstract What is 'insignificant' prostate carcinoma?
Cancer. 2004 Nov 1;101(9):1923-5. No abstract available.
PMID: 15372479 [PubMed - indexed for MEDLINE]
13: Bastian PJ, Mangold LA, Epstein JI, Partin AW. Related Articles, Links
Abstract Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis.
Cancer. 2004 Nov 1;101(9):2001-5.
PMID: 15372478 [PubMed - indexed for MEDLINE]
14: Ogawa R, Kagiya G, Feril LB Jr, Nakaya N, Nozaki T, Fuse H, Kondo T. Related Articles, Links
Abstract Ultrasound mediated intravesical transfection enhanced by treatment with lidocaine or heat.
J Urol. 2004 Oct;172(4 Pt 1):1469-73.
PMID: 15371873 [PubMed - indexed for MEDLINE]
15: Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML. Related Articles, Links
Abstract The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy.
J Urol. 2004 Oct;172(4 Pt 1):1328-32.
PMID: 15371834 [PubMed - indexed for MEDLINE]
16: Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, Breed S, Somerville M, Rittmaster R; REDUCE Study Group. Related Articles, Links
Abstract Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
J Urol. 2004 Oct;172(4 Pt 1):1314-7.
PMID: 15371831 [PubMed - indexed for MEDLINE]
17: Lorenzato M, Rey D, Durlach A, Bouttens D, Birembaut P, Staerman F. Related Articles, Links
Abstract DNA image cytometry on biopsies can help the detection of localized Gleason 3+3 prostate cancers.
J Urol. 2004 Oct;172(4 Pt 1):1311-3.
PMID: 15371830 [PubMed - indexed for MEDLINE]
18: Poulakis V, Witzsch U, De Vries R, Emmerlich V, Meves M, Altmannsberger HM, Becht E. Related Articles, Links
Abstract Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage.
J Urol. 2004 Oct;172(4 Pt 1):1306-10.
PMID: 15371829 [PubMed - indexed for MEDLINE]
19: Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF 3rd. Related Articles, Links
Abstract Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
J Urol. 2004 Oct;172(4 Pt 1):1302-5.
PMID: 15371828 [PubMed - indexed for MEDLINE]
20: Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. Related Articles, Links
Abstract The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
J Urol. 2004 Oct;172(4 Pt 1):1297-301.
PMID: 15371827 [PubMed - indexed for MEDLINE]
Items 1 - 20 of 33
 
 of 2
Next  
 Show: